Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Northwestern University

キーワード

概要

Current pharmacological treatments for chronic hypersomnia (narcolepsy, idiopathic hypersomnia) can effectively reduce excessive daytime sleepiness but a high proportion of patients experience depressive symptoms and poor health-related quality of life. Unfortunately, there are currently no psychosocial interventions that directly addresses this issue. Therefore, the overall goal of this project is to gather initial outcome data and work out methodological issues to determine if a future pragmatic clinical trial is warranted.

説明

Chronic hypersomnia (CH) is a serious and debilitating condition involving persistent excessive daytime sleepiness (EDS) and includes narcolepsy and idiopathic hypersomnia (IH). Currently, pharmacotherapy is the only empirically-validated treatment for reducing EDS in this patient population but the burden of long-term management and adverse effects of the medication lead to poor health-related quality of life (HRQoL) and elevations in depressive symptoms

Evidence-based psychosocial interventions have been developed in other areas to improve HRQoL related to chronic illnesses, such as cancer and chronic pain. These interventions typically involve a package of cognitive and behavioral techniques teaching coping skills (e.g., emotion-focused and problem-focused coping), behavioral management of the chronic illness symptoms (e.g., relaxation for pain management), and other strategies to improve psychosocial functioning (e.g., mindfulness). However, no such interventions have been developed or used for people with CH. Therefore, a major research gap exists for an empirically-validated psychosocial intervention which is aimed directly at improving emotional functioning and HRQoL for people with CH.

The purpose of this project is to develop a cognitive-behavioral treatment for hypersomnia (CBT-H) and conducting a feasibility trial of CBT-H. The specific aims for this project are to: 1) develop and refine a treatment protocol for CBT-H; 2) identify the optimal delivery format of CBT-H; and 3) gather feasibility data on recruitment, retention, and selection criteria for a future clinical trial. The overall significance of this project is to improve the quality of care for people with CH by using a psychosocial intervention with medical management of hypersomnia.

日付

最終確認済み: 10/31/2019
最初に提出された: 04/02/2019
提出された推定登録数: 04/02/2019
最初の投稿: 04/04/2019
最終更新が送信されました: 11/18/2019
最終更新日: 11/20/2019
実際の研究開始日: 12/09/2018
一次完了予定日: 09/29/2019
研究完了予定日: 10/06/2019

状態または病気

Narcolepsy
Idiopathic Hypersomnia

介入/治療

Behavioral: Cognitive-Behavior Therapy for Hypersomnia (CBT-H)

段階

-

アームグループ

介入/治療
Experimental: CBT-H (Individual format)
Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
Experimental: CBT-H (Group format)
Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

1. Males and females age 18 and older.

2. Meets criteria for Narcolepsy (Type I or II) or Idiopathic Hypersomnia (IH).

3. Moderate to severe symptoms of depression.

4. Established standard care for CH at a sleep clinic.

Exclusion Criteria:

1. Hypersomnia not of central origin.

2. Current suicidal ideation or intent.

3. Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol.

4. Inability to engage in the treatment protocol due to a psychiatric or cognitive issue.

5. Untreated moderate-to-severe sleep-related breathing disorder.

6. Unable to attend intervention sessions due to accessibility or availability.

結果

主な結果の測定

1. Patient Health Questionnaire (PHQ) [Change from Baseline PHQ at 6 weeks (Post-treatment)]

The PHQ is a 9-item self-report scale of depressive symptoms that has been validated to assess the severity of depression in clinical practice. PHQ-9 cut scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

二次的な結果の測定

1. Patient Reported Outcomes Measurement Information System (PROMIS) Self Efficacy Scale [Baseline to post-treatment (6 weeks)]

Measures general self-efficacy, self-efficacy for managing emotions, self-efficacy for managing social interactions, self-efficacy for managing symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting better self-efficacy.

2. Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale [Baseline to post-treatment (6 weeks)]

Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.

3. Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale [Baseline to post-treatment (6 weeks)]

Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.

4. Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Scale [Baseline to post-treatment (6 weeks)]

Measures sleep disturbances using Computer Adaptive Testing (CAT) with higher scores reflecting more sleep disturbance.

5. Patient Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Scale [Baseline to post-treatment (6 weeks)]

Measures sleep-related impairment using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.

6. Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale [Baseline to post-treatment (6 weeks)]

Measures fatigue using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.

7. Patient Reported Outcomes Measurement Information System (PROMIS) Phyiscal Function Scale [Baseline to post-treatment (6 weeks)]

Measures physical function using Computer Adaptive Testing (CAT) with higher scores reflecting better physical function.

8. Epworth Sleepiness Scale (ESS) [Baseline to post-treatment (6 weeks)]

The ESS consists of eight questions rated from 0 to 3, with higher scores indicating greater likelihood of falling asleep. Total scores of 10 or greater reflect excessive daytime sleepiness.

9. Functional Outcomes of Sleep Questionaire (FOSQ) [Baseline to post-treatment (6 weeks)]

The FOSQ assesses the impact of sleepiness on daily behaviors and quality of life. It is comprised of 30 items divided into five subscales: activity level, vigilance, intimate and sexual relationships, general productivity, and social outcome. Items are rated from 1 to 4, with higher score reflecting better functioning.

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge